Ascenta Therapeutics, Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Ascletis Inc. , a Chinese biotech specializing in liver disease treatments with a focus on hepatitis C, has completed a major $100m Series B financing, following a first round $55m fundraising in the

In Vitro Diagnostics Mergers & Acquisitions /In Vitro Diagnostics Alere Inc. VitaPath Genetics Inc. Diagnostics company Alere Inc. has licensed global marketing rights to VitaPath Genetics Inc.

The Swiss Debiopharm Group and US-based Ascenta Therapeutics have entered into an exclusive worldwide license development and commercialisation agreement for the Phase I compound, AT-406 (also, Debio